Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.

[1]  M. Ye,et al.  Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study , 2019, Journal of Ovarian Research.

[2]  P. Brastianos,et al.  Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. , 2019, Gynecologic oncology.

[3]  J. Baumbach,et al.  Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes , 2019, BMC Cancer.

[4]  A. Oza,et al.  Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations , 2019, Cancers.

[5]  C. Le Page,et al.  Prognostic value of progesterone receptor expression in tubo‐ovarian high‐grade serous carcinoma of the COEUR cohort , 2019, Histopathology.

[6]  D. Stoppa-Lyonnet,et al.  GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers , 2018, Front. Oncol..

[7]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[8]  Annette Lee,et al.  Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations , 2018, Human mutation.

[9]  C. Le Page,et al.  Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.

[10]  S. Mok,et al.  Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision , 2018, Cancers.

[11]  R. Palmirotta,et al.  Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family , 2018, International journal of molecular sciences.

[12]  M. Sekine,et al.  Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan , 2017, Journal of Human Genetics.

[13]  P. Chappuis,et al.  Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer , 2017, Clinical Cancer Research.

[14]  L. Senter,et al.  BRCA mutation in ovarian cancer: testing, implications and treatment considerations , 2017, Therapeutic advances in medical oncology.

[15]  X. Pivot,et al.  First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report. , 2017, Oncology reports.

[16]  Olufunmilayo I. Olopade,et al.  Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women , 2016, Breast Cancer Research.

[17]  M. Adank,et al.  Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers , 2016, British Journal of Cancer.

[18]  R. Elkon,et al.  BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. , 2016, The Journal of clinical investigation.

[19]  S. Leung,et al.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  Mads Thomassen,et al.  Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. , 2015, JAMA.

[21]  A. Mes-Masson,et al.  A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population , 2015, Journal of Ovarian Research.

[22]  M. De Paola,et al.  Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family , 2013, Clinical chemistry and laboratory medicine.

[23]  P. Mehdipour,et al.  A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer , 2013, BioMed research international.

[24]  A. Whittemore,et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.

[25]  C. Le Page,et al.  Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. , 2013, Biopreservation and biobanking.

[26]  Caroline Seynaeve,et al.  The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers , 2013, Cancer.

[27]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[28]  Alexia Iasonos,et al.  Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer , 2012, Cancer.

[29]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Jonat,et al.  Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management , 2012, Breast Cancer Research and Treatment.

[31]  Narciso Olvera,et al.  Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma , 2012, Modern Pathology.

[32]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[33]  G. Hortobagyi,et al.  Earlier age of onset of BRCA mutation‐related cancers in subsequent generations , 2012, Cancer.

[34]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[35]  D. Noh,et al.  The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[36]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[37]  M. Martino,et al.  Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities , 2011, Breast Cancer Research and Treatment.

[38]  Barry Rosen,et al.  Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.

[39]  G. Rennert,et al.  Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  W. Foulkes,et al.  BRCA1 and BRCA2 families and the risk of skin cancer , 2010, Familial Cancer.

[41]  S. Tommasi,et al.  Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report , 2010, Breast Cancer Research and Treatment.

[42]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Janavicius.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control , 2010, EPMA Journal.

[44]  T. Hansen,et al.  Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations , 2010, Familial Cancer.

[45]  P. Radice,et al.  Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics , 2010, Breast Cancer Research and Treatment.

[46]  B. Ward,et al.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer , 2009, Cancer.

[47]  A. Howell,et al.  Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[48]  S. Cascio,et al.  Founder mutations in BRCA1 and BRCA2 genes. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  A. Sood,et al.  Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. , 2007, American journal of obstetrics and gynecology.

[50]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[51]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[52]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[53]  R. Eeles,et al.  Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations , 2005, Journal of Medical Genetics.

[54]  B. Haffty,et al.  Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[56]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[57]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[58]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[59]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[60]  J. Godino,et al.  A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes , 2002, Journal of medical genetics.

[61]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Narod,et al.  An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2 , 2000, Clinical genetics.

[63]  A. Mes-Masson,et al.  Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history , 1999, Clinical genetics.

[64]  R. Gershoni-baruch,et al.  Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. , 1998, American journal of human genetics.

[65]  J. Boyd,et al.  Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. , 1998, Gynecologic oncology.

[66]  S. Narod,et al.  A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. , 1998, American journal of human genetics.

[67]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[68]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[69]  B. Ponder,et al.  A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2 , 1997, Nature Genetics.